Care Options
Canine Adenovirus Type 1 Vaccine: What Dogs Need to Know
The canine adenovirus type 2 (CAV-2) vaccine protects dogs against canine adenovirus type 1 (CAV-1), the virus responsible for infectious canine hepatitis.
Key takeaways
The canine adenovirus type 2 (CAV-2) vaccine protects dogs against canine adenovirus type 1 (CAV-1), the virus responsible for infectious canine hepatitis.
- CAV-1 vaccination is an important part of canine preventive healthcare, but the vaccine most dogs receive does not actually contain CAV-1.
- Modern veterinary vaccines use a related virus, CAV-2, to provide protection against both adenovirus types while avoiding certain complications associated with older CAV-1 vaccines.
- Understanding this distinction helps when reviewing vaccination records, choosing a vaccine schedule, or deciding whether a dog needs a booster.
1. What Is Canine Adenovirus Type 1?
Canine adenovirus type 1 (CAV-1) is a contagious virus that causes infectious canine hepatitis, a disease that primarily affects dogs but can also infect certain wild carnivores.
The virus can damage several organs, including:
• Liver: Infection can cause hepatitis and damage to liver cells.
• Kidneys: Inflammation and immune reactions can cause kidney damage.
• Blood vessels: Damage to blood vessel walls can cause bleeding and problems with blood clotting.
• Eyes: Immune reactions can cause inflammation and corneal clouding, sometimes called blue eye.
Infectious canine hepatitis can range from mild illness to severe, potentially fatal disease. Young puppies are particularly vulnerable.
The disease has become uncommon in areas where routine canine vaccination is practiced, but infections and occasional outbreaks still occur.
2. Does the CAV-1 Vaccine Actually Contain CAV-1?
Usually, no. Modern core canine vaccines generally contain modified-live CAV-2 rather than CAV-1.
The distinction is important:
• Virus — Main disease association — Role in vaccination
• CAV-1 — Infectious canine hepatitis — The disease the vaccine protects against
• CAV-2 — Respiratory disease, including infectious tracheobronchitis — Used in vaccines to provide protection against CAV-1
CAV-1 and CAV-2 are related viruses. Vaccination with modified-live CAV-2 stimulates strong immune protection against CAV-1, as well as protection against CAV-2.
Consequently, dogs generally do not need a separate CAV-1 vaccine. The CAV-2 component of their routine core vaccination provides the necessary protection against infectious canine hepatitis.
3. Why Was the Original CAV-1 Vaccine Replaced?
Older canine vaccines sometimes contained modified-live CAV-1.
Although these vaccines could protect against infectious hepatitis, they occasionally caused a temporary eye complication called blue eye, or corneal edema.
This complication occurs when inflammation and immune reactions cause the cornea, the transparent outer surface of the eye, to become cloudy.
Older live CAV-1 vaccines could also result in viral shedding in urine.
Modern modified-live CAV-2 vaccines offer several advantages:
• Strong cross-protection against CAV-1.
• Protection against CAV-2.
• Avoidance of the characteristic vaccine-associated corneal edema seen with older CAV-1 vaccines.
• No urinary shedding of the vaccine virus described with older live CAV-1 vaccines.
The replacement of CAV-1 with CAV-2 in modern core vaccines is therefore an important improvement in canine vaccination.
4. When Should Dogs Receive the CAV-2 Vaccine?
CAV-2 vaccination is considered a core vaccine, meaning it is recommended for dogs regardless of lifestyle because it protects against a potentially serious infectious disease.
The recommended schedule depends on the dog's age and vaccination history.
Puppy vaccination schedule
The general schedule recommended by WSAVA and UC Davis is:
• Puppy age — Recommended vaccination
• 6 to 8 weeks — Begin the core combination vaccine
• Every 3 to 4 weeks afterward — Continue vaccinations
• 16 weeks or older — Give the final vaccination in the initial series
• Around 6 months — Give an additional booster
In particularly high-risk situations, WSAVA recommends continuing the initial series until approximately 20 weeks of age.
Repeated vaccinations are necessary because antibodies received from the mother can interfere with a puppy's ability to develop its own immunity. These maternal antibodies gradually decline, which is why the vaccination series extends beyond the earliest puppy vaccinations.
Adult dog vaccination schedule
For dogs older than 16 weeks:
• Dogs with no reliable vaccination history need an appropriate initial core vaccination plan.
• UC Davis recommends two vaccinations containing modified-live CAV-2, generally separated by 3 to 4 weeks.
• WSAVA notes that some manufacturers recommend two vaccinations, although one modified-live core vaccination will likely protect most adult dogs.
• After the initial series and subsequent booster, core adenovirus revaccination should generally occur no more frequently than every three years.
The exact schedule should follow the specific vaccine's approved labeling and the dog's medical history.
Do senior dogs still need the vaccine?
Reaching an advanced age does not automatically eliminate the need for core vaccination. WSAVA recommends continuing core vaccination throughout a dog's life, generally at intervals of at least three years after the initial series and booster.
A previous serious vaccine reaction, immune-related condition, or other medical concern may change the recommendation and should be considered individually.
5. Which Canine Adenovirus Vaccine Should You Look For?
Most dogs receive CAV-2 protection through a combination vaccine rather than a separate adenovirus injection.
These combination vaccines commonly contain:
• Canine distemper virus protection.
• Canine adenovirus type 2 protection.
• Canine parvovirus protection.
• Sometimes canine parainfluenza protection.
When reviewing vaccination records, look for wording such as:
• Canine adenovirus type 2.
• CAV-2.
• Modified-live CAV-2.
• Distemper, adenovirus, and parvovirus combination vaccine.
The important detail is whether the product contains the CAV-2 component used for core protection against infectious canine hepatitis.
Injectable versus intranasal adenovirus vaccines
This distinction is particularly important.
Some intranasal respiratory vaccines contain CAV-2 alongside Bordetella and canine parainfluenza. These products are intended for respiratory disease prevention and are classified separately from the injectable core combination vaccine in WSAVA guidelines.
If a vaccination record only mentions an intranasal kennel cough vaccine, ask the veterinary practice whether the dog also received the injectable core CAV-2 vaccine.
The two products should not automatically be treated as interchangeable.
6. CAV-2 Vaccine Side Effects and Safety
Modern CAV-2 vaccines are generally well tolerated and avoid the characteristic corneal complications associated with older CAV-1 vaccines.
However, like other canine vaccines, they can cause adverse reactions.
Common, usually mild reactions
Some dogs experience temporary:
• Tenderness or swelling at the injection site.
• Reduced appetite.
• Tiredness or decreased activity.
• Mild fever.
• Small, firm swelling where the vaccine was administered.
These reactions generally resolve without treatment. Contact the veterinary practice if symptoms worsen, persist beyond a day or two, or cause significant discomfort.
Serious allergic reactions
Severe allergic reactions are uncommon but can be life-threatening. They may develop within minutes to hours following vaccination.
Seek emergency veterinary care immediately if any of these signs develop:
• Difficulty breathing.
• Collapse or fainting.
• Swelling of the face, muzzle, eyes, or neck.
• Widespread itchy bumps or hives.
• Persistent vomiting or diarrhea.
• Severe or persistent coughing.
A dog with a previous vaccine reaction should have that history reviewed before another vaccination. The veterinary practice can consider the previous product, reaction, vaccination history, and whether antibody testing would help guide the decision.
7. Can Antibody Testing Confirm Protection Against CAV-1?
Yes.
Blood testing can detect antibodies against canine adenovirus and help assess whether a dog has developed an immune response following vaccination.
This is called antibody titer testing or serological testing.
A positive antibody result in an adult dog that has developed its own active immune response is generally considered evidence of protection against CAV.
Testing can be particularly useful when:
• A dog has previously experienced a serious vaccine reaction.
• There is uncertainty about whether a puppy responded to its initial vaccination series.
• An owner and veterinarian want to assess immunity before deciding on another booster.
• A dog is receiving medication that significantly suppresses the immune system.
However, not all antibody tests are equally reliable.
WSAVA recommends that gold-standard laboratory testing is generally more reliable for detecting CAV antibodies than convenient in-clinic testing kits. Some in-practice CAV antibody tests have demonstrated poor specificity, which can produce misleading results.
For puppies, WSAVA describes checking a blood sample at or after 20 weeks of age and at least four weeks after the last vaccination in the initial series to assess whether active immunity developed.
Titer testing is an option to discuss with a veterinarian, not an automatic replacement for routine vaccination in every dog.
8. What Happens If a Dog Is Not Protected Against CAV-1?
Without adequate immunity, a dog remains vulnerable to infectious canine hepatitis.
CAV-1 is transmitted primarily through contact with infected dogs' urine, feces, or saliva. Contaminated objects and other environmental exposures can also contribute to transmission.
Dogs that recover from infection can continue shedding the virus in their urine for at least six months. The virus can also survive in the environment for weeks or months.
Signs of infectious canine hepatitis
The disease can develop rapidly, and symptoms vary considerably.
Possible signs include:
• Fever.
• Lethargy and weakness.
• Loss of appetite.
• Increased thirst.
• Eye inflammation or discharge.
• Cloudiness of the cornea, sometimes called blue eye.
• Vomiting.
• Abdominal pain.
• Bruising, small red or purple spots, or abnormal bleeding.
• Swelling of the head, neck, or body.
Severe infections can cause liver damage, blood-clotting disorders, kidney complications, seizures, and death.
When veterinary attention is necessary
A dog showing unexplained fever, vomiting, eye inflammation, or marked lethargy should be assessed promptly, particularly if vaccination history is incomplete.
Suspected bleeding disorders, collapse, severe weakness, or seizures warrant emergency veterinary care.
If infectious canine hepatitis is suspected, contact the veterinary practice before arriving and keep the dog away from other dogs while awaiting instructions. This helps reduce the risk of exposing other animals.
Diagnosis can involve PCR testing, ELISA, or serological testing. Treatment is primarily supportive and may include intravenous fluids, nutritional support, management of blood-clotting problems, and treatment of secondary bacterial infections.
Vaccination before exposure remains the most effective preventive approach.
Frequently asked questions
Is canine adenovirus type 1 the same as canine hepatitis?
CAV-1 is the virus responsible for infectious canine hepatitis. CAV-2 is a related virus used in modern vaccines because it stimulates protective immunity against CAV-1.
Does the DHPP or DAPP vaccine protect against canine adenovirus type 1?
A combination vaccine containing modified-live CAV-2 provides protection against CAV-1. Check the actual product information or vaccination record to confirm that it contains the appropriate adenovirus component.
Does a dog need both CAV-1 and CAV-2 vaccines?
No. Modern core CAV-2 vaccination provides strong cross-protection against CAV-1, so a separate CAV-1 vaccine is generally unnecessary.
Is the canine adenovirus vaccine given every year?
Not necessarily. Following the initial vaccination series and booster, WSAVA and UC Davis recommend core CAV revaccination no more frequently than every three years. The schedule should account for the product label and individual medical circumstances.
Can a vaccinated dog still develop infectious canine hepatitis?
Vaccination provides strong protection, but an incomplete puppy series or failure to develop an adequate immune response can leave a dog susceptible. Maternal antibodies can interfere with early vaccination, which is why the final puppy vaccination is particularly important.
Is the CAV-1 vaccine responsible for blue eye?
Older modified-live CAV-1 vaccines occasionally caused temporary corneal clouding known as blue eye. Modern CAV-2 core vaccines were adopted because they provide cross-protection without this characteristic vaccine-associated corneal complication.
Can an older dog receive a CAV-2 vaccine?
Yes. Age alone is not a reason to discontinue core adenovirus vaccination. The dog's previous vaccination history, medical conditions, and any history of adverse reactions should guide the schedule.
Can a dog receive the CAV-2 vaccine if it has never been vaccinated?
Yes. Unvaccinated adult dogs can receive core adenovirus vaccination. The initial schedule depends on the product, age, and vaccination history. A veterinarian can establish the appropriate catch-up plan.
Editorial standards
Who wrote this guide
Written by VetWayfinder Editorial Team.
Every factual statement is tied to a cited source listed below. Report an error through the corrections page.
Sources
Each source supports at least one factual statement in this guide.
